We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
-$143M
Cap. Flow
-$225M
Cap. Flow %
-13.99%
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$21.4M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.6M
3
OMDA
Omada Health Inc
OMDA
+$15.9M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$12.1M
5
ACLX
Arcellx
ACLX
+$11.6M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$85.4M
2
NUVL
Nuvalent
NUVL
+$24.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$21.8M
4
UNH icon
UnitedHealth
UNH
+$19.1M
5
LEGN icon
Legend Biotech
LEGN
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEN icon
76
Compugen
CGEN
$221M
$1.76M 0.11%
989,990
– –
SION
77
Sionna Therapeutics
SION
$203M
$1.73M 0.11%
99,429
– –
LUNG icon
78
Pulmonx
LUNG
$97.9M
$1.69M 0.11%
651,100
+147,400
+29% +$581K
NGNE icon
79
Neurogene
NGNE
$729M
$1.56M 0.1%
104,339
– –
CATX icon
80
Perspective Therapeutics
CATX
$342M
$1.53M 0.1%
444,383
– –
APLS
81
DELISTED
Apellis Pharmaceuticals
APLS
$1.46M 0.09%
84,300
+4,300
+5% +$79.6K
SRPT icon
82
Sarepta Therapeutics
SRPT
$1.81B
$1.17M 0.07%
68,600
-90,700
-57% -$3.87M
MRSN
83
DELISTED
Mersana Therapeutics
MRSN
$1.13M 0.07%
152,587
– –
APLT
84
DELISTED
Applied Therapeutics
APLT
$646K 0.04%
2,075,991
+1,100
+0.1% +$426
ADAP
85
DELISTED
Adaptimmune Therapeutics
ADAP
$595K 0.04%
2,483,468
– –
KRRO icon
86
Korro Bio
KRRO
$199M
$446K 0.03%
35,719
– –
CRL icon
87
Charles River Laboratories
CRL
$13.2B
$410K 0.03%
+2,700
New +$360K
ETNB
88
DELISTED
89bio
ETNB
$393K 0.02%
40,000
-804,441
-95% -$6.66M
PCVX icon
89
Vaxcyte
PCVX
$8.67B
$361K 0.02%
+11,100
New +$364K
NVAX icon
90
Novavax
NVAX
$1.3B
$340K 0.02%
53,900
-596,100
-92% -$3.95M
TLPH icon
91
Talphera
TLPH
$73.2M
$146K 0.01%
316,460
– –
NUVB.WS
92
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$36.2K ﹤0.01%
134,028
– –
BCRX icon
93
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-222,011
Closed -$1.67M
BEAM icon
94
Beam Therapeutics
BEAM
$2.82B
– –
-150,020
Closed -$2.93M
INZY
95
DELISTED
Inozyme Pharma
INZY
– –
-3,445,299
Closed -$3.14M
LEGN icon
96
Legend Biotech
LEGN
$4B
– –
-512,932
Closed -$17.4M
MGNX icon
97
MacroGenics
MGNX
$259M
– –
-1,145,214
Closed -$1.45M
PLRX icon
98
Pliant Therapeutics
PLRX
$64.4M
– –
-589,996
Closed -$796K
SGMT icon
99
Sagimet Biosciences
SGMT
$591M
– –
-787,808
Closed -$2.57M
VIGL
100
DELISTED
Vigil Neuroscience
VIGL
– –
-471,958
Closed -$840K
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rock Springs Capital Management held 105 positions worth $1.6B, down 8.2% from $1.75B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $225M in Q2 2025, closing 12 positions and reducing 29 holdings. Its most notable exit was Legend Biotech, an estimated $17.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Caris Life Sciences worth $21.2M.

  • Rock Springs Capital Management's largest Q2 2025 buy was Caris Life Sciences: 793,651 shares worth $21.2M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q2 2025, an estimated $19.6M increase.
  • Rock Springs Capital Management's biggest Q2 2025 reduction was Blueprint Medicines, cutting an estimated $85.4M.
  • Rock Springs Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $17.4M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $1.6B portfolio in Q2 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 12 in Q2 2025.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.